Paul Richardson, MD
Dana Farber Cancer Institute
Interview Date: June 1, 2020
Myeloma progress continues in 2020 as additional therapies continue through the clinical trial process. This is great news for myeloma patients. One of the best mid-year meetings is the American Society of Clinical Oncology. Held virtually this year, Paul Richardson, MD of the Dana Farber Cancer Institute shares updates on key announcements. This includes the difference between two triplet combinations - Kyprolis/Revlimid/Dex vs. Velcade/Revlimid/Dex which had surprising results. He also shares updates on the monoclonal antibodies isatuximab and daratumumab. Dr. Richardson reviews CAR T data about the bb2121 CAR T therapy expected to be approved as the first CAR T in myeloma. He also reviews additional therapies that were recently approved, like selinexor, or others that are close to approval like venetoclax (for 4;14 myeloma patients) and a new antibody drug conjugate called belantamab mafodotin. It's key to stay up-to-date on approvals and clinical trials so you know what's coming in myeloma care. It's exciting!
Thanks to our episode sponsor GlaxoSmithKline
Paul Richardson, MD, is the RJ Corman Professor of Medicine at the Harvard Medical School, Clinical Program Leader and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, of the Dana-Farber Cancer Institute (DFCI) in Boston. Dr. Richardson received his medical degree from the Medical College of St. Bartholomew’s Hospital in London, UK. His postdoctoral training included internship in the Departments of Medicine & Surgery at St. Bartholomew’s Hospital; residency in the Department of Medicine at Newcastle University School of Medicine; appointment as Chief Resident in Medical Oncology at the Royal Marsden Hospital in London and Surrey; and additional residency training at the Beth Israel Hospital in Boston, USA. He completed fellowships in hematology/oncology and medical oncology at Tufts University School of Medicine, Baystate Medical Center, and Harvard Medical School, Dana-Farber Cancer Institute before coming on staff at DFCI in 1994. Dr. Richardson currently holds leadership positions in several professional bodies and serves on the Editorial Board of the Journal of Clinical Oncology, the Journal of Oncology, The Oncologist, Clinical Cancer Research, and the British Journal of Hematology. He is the prior Chairman of the Multiple Myeloma Research Consortium, Clinical Trials Core, a position he held for 5 years as a founding member and as part of a rotating tenure, and for which he continues to serve on the Steering Committee and Project Review Committee. He now chairs the newly formed Multiple Myeloma Committee for the Alliance for Clinical Trials in Oncology (the former CALGB). His honors include several Massachusetts General Hospital, Brigham and Women’s Hospital, and Dana-Farber Partners in Excellence Awards; The Brigham and Women’s Hospital Teaching Scholars Award; The Tisch Outstanding Achievement Award for Clinical Research; and the Dana-Farber Cancer Institute’s George Canellos Award for Excellence in Clinical Research and Patient Care. For his contributions in hematology and oncology, and in particular myeloma, he was awarded an honorary Fellowship of the Royal College of Physicians (FRCP) in 2009, and he was also more recently a co-recipient of the prestigious Warren Alpert Prize in 2012, the Ernest Beutler Prize at ASH 2015, and the Robert A Kyle Lifetime Achievement Award in 2017.
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113